SBRT and puterizumab for lung metastases
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of targeted radiation (SBRT) and an immunotherapy drug (puterizumab) for people whose non-small cell lung cancer has spread to the lungs after previous immunotherapy. The goal is to see if the combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your non-small cell lung cancer has spread to your lungs after you had immunotherapy (like Keytruda or similar drugs) in the past.
- You are willing to have a lung needle biopsy and have lung tumors that can be seen on CT scan.
- Your overall health is good, meaning you can do most daily activities (ECOG score 0 or 1).
- Your blood work and kidney/liver function are within certain safe limits (doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
This trial studies a precise, high-dose radiation technique (SBRT) to treat tumors in the lungs. It may help control cancer in people who either have early-stage lung cancer that is not fully operable or have limited lung metastases from other cancers.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.